RxDoctor Payments Data

Kristen Battiato

Gerontology · Staten Island, NYNPI 1316478589

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,861 of the $15,105 with a category attached, or 71.9%. AbbVie accounts for 60.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $7,552 and has fallen 99.3% since, to $50 in 2025. Among gerontology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,105in general payments, 2019–2025

Across 43 payments — averaging $351.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Lilly USA, LLC$2K
  • Beigene USA, Inc.$2K
  • TG Therapeutics, Inc.$750
  • AstraZeneca$457
  • Pharmacyclics LLC, An Abbvie Company$227
  • plus $498 from 7 others

What the payments were for

  • Consulting fees$10,86172%
  • Travel & lodging$2,04714%
  • Food & beverage$2,17814%
  • Education$180%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,105 in reported general payments places this provider in the 95th percentile of 187 gerontology providers in New York.

See all gerontology providers in New York

Medicare billing

Part B allowed, 2024
$4,357
Medicare patients
37
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib30$494,520
CalquenceAcalabrutinib Maleate22$388,020
BrukinsaZanubrutinib13$175,850
VenclextaVenetoclax20$131,496
Imatinib Mesylate20$3,068
Acyclovir17$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$227$494,52030 claims
AstraZenecaCalquence$457$388,02022 claims
Beigene USA, Inc.Brukinsa$1,977$175,85013 claims
AbbVieVenclexta$9,096$131,49620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 gerontology providers in New York.

Other gerontology in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →